TMEM132D Inhibitors
Chemical inhibitors of TMEM132D can modulate its activity through various molecular pathways by targeting different enzymes and kinases that lie upstream of this protein. LY294002 and Wortmannin are both inhibitors of phosphoinositide 3-kinases (PI3K). Inhibition of PI3K by these chemicals results in reduced activation of AKT signaling pathways. Since AKT is necessary for the activation of several downstream proteins including TMEM132D, the inhibition of PI3K leads to decreased functional activity of TMEM132D. Similarly, Rapamycin, through its action on mTOR, a central component of the PI3K/AKT/mTOR pathway, can inhibit the activity of TMEM132D by interrupting the activation signals necessary for its functional expression.
Inhibition of the MAPK/ERK pathway also affects TMEM132D activity. U0126, PD98059, and SL327 are specific inhibitors of MEK1/2, which are upstream kinases in this pathway. By inhibiting MEK1/2, these chemicals prevent the activation of ERK, consequently reducing TMEM132D activity. SB203580 and SP600125, targeting p38 MAPK and JNK respectively, impede other branches of the MAPK signaling pathways, leading to a decrease in TMEM132D activity by obstructing the signaling cascades that would normally result in its activation. Additionally, Y-27632 inhibits the Rho-associated protein kinase (ROCK), which is involved in cytoskeletal dynamics that can affect TMEM132D activity. PP2 and Dasatinib, both Src family kinase inhibitors, prevent the phosphorylation and activation of downstream targets, including TMEM132D, thereby inhibiting its function. Lastly, Gefitinib, by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase, disrupts downstream signaling that can lead to the activation of TMEM132D, resulting in the inhibition of its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits phosphoinositide 3-kinases (PI3K), which are involved in the activation of AKT signaling. TMEM132D is known to be implicated in pathways involving AKT, and inhibition of PI3K can inhibit downstream AKT activation, thereby reducing the functional activity of TMEM132D. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 specifically inhibits MEK1/2, which are upstream kinases in the MAPK/ERK pathway. TMEM132D operates downstream of this pathway, and inhibition of MEK1/2 by U0126 can inhibit the functional activity of TMEM132D by preventing its activation through the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, which is involved in stress and inflammatory responses. Since TMEM132D is activated downstream of p38 MAPK, inhibition of this kinase by SB203580 can lead to a decrease in TMEM132D activity by obstructing the signaling cascade. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), which is part of the MAPK signaling pathways. TMEM132D, being associated with these pathways, would have reduced activity upon JNK inhibition, as SP600125 would prevent activation signals from reaching TMEM132D. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, and by inhibiting PI3K, it would decrease AKT phosphorylation. As AKT signaling is necessary for the full activation of several proteins including TMEM132D, its inhibition by Wortmannin would lead to a reduction in TMEM132D activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, which is involved in the ERK pathway. As TMEM132D is a downstream effector in this pathway, the inhibition of MEK by PD98059 can lead to a decrease in ERK activity and thereby inhibit the functional activity of TMEM132D. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a central component of the PI3K/AKT/mTOR pathway. TMEM132D is a downstream target of this pathway, and inhibition of mTOR by Rapamycin can inhibit the functional activity of TMEM132D by blocking the necessary activation signals. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 inhibits the Rho-associated protein kinase (ROCK), which can regulate actin cytoskeleton dynamics. TMEM132D has been implicated in cellular processes that are affected by changes in the cytoskeleton, and inhibition of ROCK by Y-27632 can lead to inhibition of TMEM132D activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family kinases. Src kinases can phosphorylate and activate downstream targets including TMEM132D. By inhibiting Src kinases, PP2 can prevent the phosphorylation and subsequent activation of TMEM132D, resulting in its functional inhibition. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327 is an inhibitor of MEK, preventing the activation of ERK1/2 in the MAPK pathway. Given that TMEM132D is activated downstream of the MAPK pathway, inhibition of MEK by SL327 would lead to inhibition of TMEM132D activity. | ||||||